Following a regional initiative to eliminate mother-to-child transmission of HIV and syphilis, Cuba becomes the first country to receive WHO validation for reaching the goal.
Sexual Health / STDs News From Medical News Today
Genital herpes caused by a reactivation of herpes simplex virus type 2 (HSV-2) is generally treated as a lesion in one specific area of the genital region. A new study, however, finds that the virus can frequently reactivate throughout the genital tract, an important new concept that could help guide both HSV-2 treatment and prevention. Now available online, the study appears in the Feb. 15 issue ofThe Journal of Infectious Diseases… (Source: Health News from Medical News Today)
MedWorm: Genital Herpes
Pride in London 2015, England’s biggest pride parade so far, took place last weekend, bringing together the lesbian, gay, bisexual, and transgender communities. Despite this celebration, a report from Public Health England on sexually transmitted infections (STIs) in England in 2014, published on June 23, 2015, uncovers alarming statistics in men who have sex with men (MSM). Although total STI diagnoses decreased by 0·3% in England from 2013 to 2014, diagnoses in MSM rose sharply, with syphilis increasing by 46%, gonorrhoea by 32%, chlamydia by 26%, and genital herpes and warts by 10% each. (Source: LANCET)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
A five-year international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment to suppress herpes simplex virus-2 (HSV-2), the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2. (Source: ScienceDaily Headlines)
MedWorm: Genital Herpes
Authors: Reszka NJ, Dudek T, Knipe DM The replication-defective herpes simplex virus 2 (HSV-2) dl5-29 mutant virus strain with deletions in the U(L)5 and U(L)29 genes has been shown to protect mice and guinea pigs against challenge with wild-type (wt) HSV-2 and to protect against ocular disease caused by HSV-1 infection. The dl5-29 strain is currently being prepared for clinical trials as a herpes vaccine candidate. As a possible approach to improve the efficacy of dl5-29 as a genital herpes vaccine, we replaced the U(L)41 gene encoding the virion host shutoff function (vhs) with the U(L)41 gene from HSV-1. While the HSV-2 U(L)41 and HSV-1 U(L)41 gene products have analogous functions, vhs-1 is 40-fold less active than vhs-2...Read More